What Clinicians Should Know About ITP – Insights from Samwel Mikaye
Samwel Mikaye, CEO of SaMik Medical Center, posted on LinkedIn:
”IMMUNE THROMBOCYTOPENIC PURPURA (ITP)
Definition
Immune Thrombocytopenic Purpura (ITP) is an autoimmune disorder characterized by:
• Isolated thrombocytopenia (platelets <100,000/µL)
• Caused by autoantibodies against platelet surface antigens → accelerated destruction in the spleen and reduced platelet production in the bone marrow.
Classification
1. Primary ITP
• Idiopathic (no identifiable cause).
2. Secondary ITP
• Associated with underlying conditions:
• HIV, HCV, EBV
• Autoimmune diseases (e.g., SLE)
• Drugs (heparin, quinine, sulfa drugs)
• Vaccination (rare)
Epidemiology
• Children: usually acute, post-viral, self-limiting.
• Adults: usually chronic, more common in women <40 years.
Clinical Features
• Often asymptomatic except for bleeding.
• Mucocutaneous bleeding:
• Petechiae, purpura, ecchymoses
• Epistaxis, bleeding gums, menorrhagia
• No splenomegaly (splenic enlargement suggests another diagnosis).
Key: Patient appears well despite very low platelet count.
Diagnosis
Diagnosis of exclusion.
• CBC: isolated thrombocytopenia; other cell lines normal.
• Peripheral smear: normal red/white cells, reduced platelets.
• Coagulation profile (PT/PTT): normal
If atypical features (anemia, leukopenia, splenomegaly), consider other causes (TTP, leukemia, DIC).
Tests to rule out secondary causes:
• HIV, HCV testing
• ANA (if autoimmune disease suspected)
Management
Children (acute ITP)
• Observation if mild bleeding and platelets >30,000/µL.
• If treatment needed (significant bleeding):
• Corticosteroids (Prednisone)
• OR IVIG (for rapid platelet rise)
• Anti-D immunoglobulin (if Rh+ and not splenectomized)
Adults (chronic ITP / symptomatic)
First-line treatment:
• Corticosteroids: Prednisone or Dexamethasone pulse
• OR IVIG (if severe bleeding or need rapid rise—e.g., surgery)
Second-line options (if refractory or steroid-dependent):
• Thrombopoietin receptor agonists (TPO-RAs):
• Romiplostim, Eltrombopag
• Rituximab (anti-CD20 antibody)
• Splenectomy (curative in ~60–70% cases)
Platelet transfusion only for life-threatening bleeding; not routinely effective since autoantibodies destroy transfused platelets.
Treatment Thresholds (Adults)
• Platelets ≥ 30,000/µL + no bleeding → observe
• Platelets < 30,000/µL or active bleeding → treat
Prognosis
• Children: 80% recover spontaneously.
• Adults: chronic in ~60–70%, but manageable.”
Stay informed with Hemostasis Today.
-
Apr 6, 2026, 04:46Ursula Porage Dona: Bringing the Bleeding Disorders Community Together at WFH 2026 with NNHF
-
Apr 6, 2026, 04:17Arun V J: How War Reshaped Blood Transfusion
-
Apr 6, 2026, 03:57Isabella Cieri: How TEG Is Transforming Vascular Surgery Care
-
Apr 5, 2026, 19:00Kausik Ray: Comparing Lipid Management in France vs. Rest of Europe for High Cardiovascular Risk Patients
-
Apr 5, 2026, 18:22Omar Adwan: Systematic Approach to Blood Smear Examination
-
Apr 5, 2026, 18:05Heghine Khachatryan: Rethinking Hemostatic Targets in Pregnancy for von Willebrand Disease
-
Apr 5, 2026, 17:45Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
-
Apr 5, 2026, 17:44Philip A. Chan: Occasional Heavy Drinking Leads to 3 Times Higher Liver Fibrosis Risk in MASLD
-
Apr 5, 2026, 17:42Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia